[HTML][HTML] Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
R de Haan, D Pluim, B van Triest… - Radiotherapy and …, 2018 - Elsevier
Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …
[HTML][HTML] Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
R De Haan, E Van Werkhoven, MM Van Den Heuvel… - BMC cancer, 2019 - Springer
Abstract Background Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel
radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific …
radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific …
PARP inhibitors as antitumor agents: a patent update (2013-2015)
Z Yuan, J Chen, W Li, D Li, C Chen… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: PARP inhibitors have been extensively explored as antitumor agents and have
shown potent efficacy both in vitro and in vivo. They can be used in monotherapy under the …
shown potent efficacy both in vitro and in vivo. They can be used in monotherapy under the …
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of …
CVM Verhagen, R de Haan, F Hageman… - Radiotherapy and …, 2015 - Elsevier
Background and purpose The PARP inhibitor olaparib is currently tested in clinical phase 1
trials to define safe dose levels in combination with RT. However, certain clinically relevant …
trials to define safe dose levels in combination with RT. However, certain clinically relevant …
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer …
N Bundred, J Gardovskis, J Jaskiewicz, J Eglitis… - Investigational new …, 2013 - Springer
Olaparib (AZD2281) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor with
antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with …
antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with …
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose …
3051 Background: We previously reported the comparative bioavailability of the olaparib
tablet (TAB) up to 200 mg BID, with the initial capsule formulation; gmean AUC0–T following …
tablet (TAB) up to 200 mg BID, with the initial capsule formulation; gmean AUC0–T following …
PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials
D Kamel, C Gray, JS Walia, V Kumar - Current drug targets, 2018 - ingentaconnect.com
Background: PARP inhibitors appear to offer a promising role in the accompaniment of many
of the cytotoxic agents used in the present day to combat cancer proliferation in BRCA ½ …
of the cytotoxic agents used in the present day to combat cancer proliferation in BRCA ½ …
[HTML][HTML] PARP1 rs1805407 increases sensitivity to PARP1 inhibitors in cancer cells suggesting an improved therapeutic strategy
I Abecassis, AJ Sedgewick, M Romkes, S Buch… - Scientific reports, 2019 - nature.com
Personalized cancer therapy relies on identifying patient subsets that benefit from a
therapeutic intervention and suggest alternative regimens for those who don't. A new data …
therapeutic intervention and suggest alternative regimens for those who don't. A new data …
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib
Background Olaparib is poorly soluble, requiring advanced drug delivery technologies for
adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice …
adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice …
Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy …
E Leo, J Johannes, G Illuzzi, A Zhang, P Hemsley… - Cancer Research, 2018 - AACR
Four poly (ADP-ribose) polymerase (PARP) inhibitors have now presented phase 3
monotherapy data showing compelling benefit of targeting tumours enriched with DNA …
monotherapy data showing compelling benefit of targeting tumours enriched with DNA …